Clear Search

Showing 2 results for “patient-reported outcomes” published 2024.

October 2024

ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials

Rheumatol 2024 2024;00:1–11 DOI 10.1093/rheumatology/keae269

Arnold et al. assessed musculoskeletal (MSK) inflammation in ANA-associated rheumatic diseases (RMDs) and redefined ANA-associated arthritis into two distinct multi-disease clusters based on disease activity, which may support a more targeted approach to treatment. The authors confirmed that MSK inflammation is a key feature across diagnoses and responded similarly to treatments.

more…

March 2024

Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: A cohort study with up to 11 years of follow-up

Rheumatology 2024 DOI 10.1093/rheumatology/keae120 Epub ahead of print

Patients with a lupus low disease activity state (LLDAS) irrespective of organ damage were significantly more likely to have favourable health-related quality of life, pain, fatigue, and overall health experience.

more…